Targeting the neuro-immune crosstalk in breast cancer brain metastases - PubMed
5 hours ago
- #neuro-immune crosstalk
- #immunotherapy
- #brain metastasis
- Breast cancer brain metastasis (BCBrM) is highly lethal and responds poorly to immunotherapy due to the blood-brain barrier limiting immune cell entry.
- Research focuses on new immune checkpoints like LAG3-LGALS3 and TIGIT-NECTIN2 axes to overcome immunosuppression.
- Key immunosuppressive cells include FOXP3+ Treg cells, LAMP3+ dendritic cells, CCL18+ M2-like macrophages, RGS5+ CAFs, LGALS1+ and TBK1+ microglia, and pSTAT3+ astrocytes.
- Targeting tumor-derived NAT8L, NAA metabolites, NMDAR signaling, and GABAergic reprogramming in BCBrM cells are promising strategies.
- Interventions against UBE2T/CDC42/CD276 and CCL2-CCR2/CCR4 axes can reshape the immune microenvironment and boost immunotherapy efficacy.
- The perspective outlines strategies in immune checkpoint modulation, cellular reprogramming, and neuroimmune interventions to improve BCBrM treatment.